Featuring an interview with Dr Kevin Kalinsky, including the following topics:

• Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00)
  • Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract
  • Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract
• Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17)
  • Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract
  • Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract
• NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09)
  • Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511.
• OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56)
  • Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract

CME information and select publications

Featuring an interview with Dr Eunice S Wang, including the following topics:

• Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00)
• All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39)
• Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07)
• Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14)
• Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24)
• Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54)
• Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics:

• All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00)
• Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21)
• First- and second-generation IDH inhibitors for AML (17:40)
• Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59)
• Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42)
• Novel combination approaches with menin inhibitors for AML (29:11)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics:

• Introduction: Antibody-drug conjugates in localized breast cancer (0:00)
• Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46)
• Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07)
• Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49)
• Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan after experiencing disease progression on capecitabine — Laila Agrawal, MD (38:37)
• Case: A woman in her late 50s with ER-negative, HER2-low mBC receives trastuzumab deruxtecan after experiencing disease progression on sacituzumab govitecan — Kimberly Ku, MD (44:24)
• Case: A woman in her early 60s with ER-positive, HER2-low mBC and hyperglycemia receives trastuzumab deruxtecan after experiencing disease progression on capivasertib/fulvestrant — Eleonora Teplinsky, MD (48:50)

CME information and select publications

Featuring perspectives from Dr Carla Casulo and Dr Brad S Kahl:

• Introduction (0:00)
• Faculty Data and Case Presentation — Dr Kahl (6:38)
• Faculty Data and Case Presentation — Dr Casulo (25:38)

CME information and select publications

Featuring an interview with Dr Laura Huppert, including the following topics:

• General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
• Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
• Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
• Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
• Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
• CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
• Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
• Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
• Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
• Ongoing evaluation of ADCs in the localized disease setting (35:42)
• Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

• Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
• Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
• Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie and Dr Laurie H Sehn, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Integrating Bispecific Antibodies into the Management of Follicular Lymphoma (FL) — Dr Crombie (2:08)
• ICurrent Role of CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for FL — Dr Abramson (21:01)
• Other Recently Approved and Emerging Novel Therapies for Relapsed/Refractory FL — Dr Sehn (40:52)

CE information and select publications